Mycobacterium tuberculosis uses sophisticated secretion systems, named 6 kDa early secretory
antigenic target (ESAT6) protein family secretion (ESX) systems (also known as type VII …

Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based
methods being considered the gold standard for drug susceptibility testing, molecular …

Lengthy, antimicrobial therapy targeting the pathogen is the mainstay of conventional
tuberculosis treatment, complicated by emerging drug resistances. Host-directed therapies, …

Mycobacterium tuberculosis (Mtb) uses efficient strategies to evade the eradication by
professional phagocytes, involving—as recently confirmed—escape from phagosomal …

Recent studies portend a rising global spread and adaptation of human- or healthcare-associated
pathogens. Here, we analyse an international collection of the emerging, multidrug-…

… Groschel et al. describe the virulenceneutral expression of the ESX-1 type VII secretion
system of Mycobacterium marinum in the attenuated BCG vaccine. ESX-1-marinum enables …

For eradication of tuberculosis (TB) by 2050, the declared aim of the Stop TB Partnership,
novel treatment strategies are indispensable. The emerging epidemic of multi-drug resistant (…

Long diagnostic wait times hinder international efforts to address antibiotic resistance in M.
tuberculosis. Pathogen whole genome sequencing, coupled with statistical and machine …

Tuberculosis (TB) has scourged humankind for millennia, and latent infection affects nearly
one-third of today’s world population. The emergence of multidrug-resistant (MDR)-TB is a …

The implementation of next generation sequencing techniques, such as whole-genome
sequencing (WGS), in tuberculosis (TB) research has enabled timely, cost-effective, and …